Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.
|Articles|July 16, 2004
Densitometry firm reaches milestone
Alara has shipped its 500th peripheral bone densitometer. The economical tabletop system is designed for in-office bone mineral density testing. The company began distributing MetriScan, which uses radiographic absorptiometry to scan a patient's three
Advertisement
Alara has shipped its 500th peripheral bone densitometer. The economical tabletop system is designed for in-office bone mineral density testing. The company began distributing MetriScan, which uses radiographic absorptiometry to scan a patient's three middle fingers, in 2002. It is available in the U.S. and 21 other countries.
Advertisement
Related to this article
The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.
The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.
In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
3
What’s Next for AI in Radiology?: Facilitating Data Orchestration Over Fragmentation
4
Could Photon-Counting CT Have an Impact as a Platform for Molecular Imaging?
5